Saniona's Pipeline

Product to target

Indication

Preclinical Research Preclinical Development Clinical Phase 1 Clinical Phase 2 Clinical Phase 3

Tesofensine monotherapy

Obesity

Tesomet

Type 2 diabetes

Prader-Willi syndrome

NS2359

Cocaine addiction

Luc Therapeutics program

Ataxia

GABAA a2/a3 program

Neuropathic Pain

Boehringer Ingelheim Program

Schizophenia

IK Program

Inflammation, IBD

Proximagen Program

Neurological disorders

Nicotinic a6 program

Parkinson's disease

In addition to the active pipeline shown above, Saniona has a range a range of validated drug discovery assets as well as clinical stage assets positioned for partnering or spin-out.